December 15, 2023 10:47 AM EST

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

AC Immune’s anti-pTau drug enters PhIIb: The Swiss biotech’s partner Johnson & Johnson launched the “potentially registration-enabling” study of ACI-35.030 in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

AC Im­mune's Alzheimer's drug heads to PhI­Ib; Cy­to­Dyn HIV drug on full hold; Syn­dax to raise $200M

News Reporter

Senior Reporter

Deputy Editor

Sign up to read this article for free.

more like this

AC Immune's Alzheimer's drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200M